← Russell 3000 cross-section

NBIX NEUROCRINE BIOSCIENCES INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$15.8bn
Revenue TTM
$3.4bn
Net income TTM
$706m
Free cash flow
$870m
Composite score
69.2
Sector rank
#524

Valuation

P / E
22.5
EV / EBITDA
18.3
EV / sales
4.6
FCF yield
5.50%
Earnings yield vs 10-yr
-0.28pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
20.9%
EBITDA margin
25.0%
ROE
19.1%
ROIC
24.1%
Revenue growth
34.4%

Insider activity, last 90 days

Net open-market
$-19.35m
Buyers
0
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Collaboration Revenues Collaboration revenues for all periods presented primarily reflected royalties earned on AbbVie net sales of elagolix and Tanabe Pharma Corporation (formerly Mitsubishi Tanabe Pharma Corporation) net sales of valbenazine. Compared with the comparable periods last year, the increase primarily reflected the progression of the Phase 3 programs for osavampator in major depressive disorder (MDD) and direclidine in schizophrenia. …NEUROCRINE BIOSCIENCES INC, 10-Q, period ended 2026-06-30, filed 2026-07-31

Read the full passage →